HGEN Humanigen Inc

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

$17.25  +0.33 (1.95%)
As of 04/09/2021 15:59:21 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2013
Outstanding shares:  53,482,364
Average volume:  6,670,340
Market cap:   $922,570,779
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    444863203
ISIN:        US4448632038
Sedol:      BM9GXF8

---

Valuation   (See tab for details)

---

PE ratio:   -28.57
PB ratio:   19.56
PS ratio:   0.00
Return on equity:   -196.59%
Net income %:   -28,697.12%